Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 344

1.

Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.

Pilli T, Cantara S, Marzocchi C, Pacini F, Prabhakar BS, Castagna MG.

Endocrine. 2019 Aug 3. doi: 10.1007/s12020-019-02028-2. [Epub ahead of print]

PMID:
31377969
2.

Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study.

Premoli P, Tanda ML, Piantanida E, Veronesi G, Gallo D, Masiello E, Rosetti S, Cusini C, Boi F, Bulla J, Rodia R, Mariotti S, Capelli V, Rotondi M, Magri F, Chiovato L, Rocchi R, Campopiano MC, Elisei R, Vitti P, Barbato F, Pilli T, Castagna MG, Pacini F, Bartalena L.

J Endocrinol Invest. 2019 Jul 20. doi: 10.1007/s40618-019-01088-5. [Epub ahead of print]

PMID:
31327128
3.

Variants in MCT10 protein do not affect FT3 levels in athyreotic patients.

Cantara S, Ricci C, Maino F, Marzocchi C, Pacini F, Castagna MG.

Endocrine. 2019 Jul 6. doi: 10.1007/s12020-019-02001-z. [Epub ahead of print]

PMID:
31280469
4.

Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma?

Capezzone M, Secchi C, Fralassi N, Cantara S, Brilli L, Ciuoli C, Pilli T, Maino F, Forleo R, Pacini F, Castagna MG.

J Endocrinol Invest. 2019 Oct;42(10):1205-1213. doi: 10.1007/s40618-019-01039-0. Epub 2019 Mar 29.

PMID:
30927240
5.

Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.

Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, Castagna MG, Toti P.

Endocrine. 2019 Apr;64(1):122-129. doi: 10.1007/s12020-019-01865-5. Epub 2019 Feb 14.

PMID:
30762153
6.

Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.

Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF.

Endocr Relat Cancer. 2019 Feb 1;26(2):241-250. doi: 10.1530/ERC-18-0258.

PMID:
30557850
7.

Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort.

Pilli T, Cardinale S, Dalmiglio C, Secchi C, Fralassi N, Cevenini G, Di Cairano G, Maino F, Forleo R, Pacini F, Castagna MG.

J Endocrinol Invest. 2019 Jun;42(6):693-698. doi: 10.1007/s40618-018-0972-3. Epub 2018 Nov 8.

PMID:
30406929
8.

Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC.

Togawa K, Ahn HS, Auvinen A, Bauer AJ, Brito JP, Davies L, Kesminiene A, Laurier D, Ostroumova E, Pacini F, Reiners C, Shinkarev S, Thomas G, Tronko M, Vaccarella S, Schüz J.

Lancet Oncol. 2018 Oct;19(10):1280-1283. doi: 10.1016/S1470-2045(18)30680-6. Epub 2018 Oct 1. No abstract available.

PMID:
30303113
9.

Preferred strategy for postsurgical thyroid ablation in low-risk thyroid cancer.

Pacini F.

Lancet Diabetes Endocrinol. 2018 Aug;6(8):590-591. doi: 10.1016/S2213-8587(18)30156-6. Epub 2018 May 26. No abstract available.

PMID:
29807825
10.

Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M, Durante C, Elisei R, Fadda G, Frasoldati A, Fugazzola L, Guglielmi R, Lombardi CP, Miccoli P, Papini E, Pellegriti G, Pezzullo L, Pontecorvi A, Salvatori M, Seregni E, Vitti P.

J Endocrinol Invest. 2018 Jul;41(7):849-876. doi: 10.1007/s40618-018-0884-2. Epub 2018 May 4.

PMID:
29729004
11.

Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC.

Maino F, Forleo R, Martinelli M, Fralassi N, Barbato F, Pilli T, Capezzone M, Brilli L, Ciuoli C, Di Cairano G, Nigi L, Pacini F, Castagna MG.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2362-2368. doi: 10.1210/jc.2018-00274.

PMID:
29672763
12.
13.

MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series.

Castagna MG, Marzocchi C, Pilli T, Forleo R, Pacini F, Cantara S.

J Endocrinol Invest. 2019 Jan;42(1):97-100. doi: 10.1007/s40618-018-0880-6. Epub 2018 Mar 24.

PMID:
29574528
14.

Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor.

Castagna MG, Forleo R, Maino F, Fralassi N, Barbato F, Palmitesta P, Pilli T, Capezzone M, Brilli L, Ciuoli C, Cantara S, Formichi C, Pacini F.

J Endocrinol Invest. 2018 Sep;41(9):1029-1035. doi: 10.1007/s40618-018-0854-8. Epub 2018 Feb 22.

PMID:
29470826
15.

Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes.

Pilli T, Toti P, Occhini R, Castagna MG, Cantara S, Caselli M, Cardinale S, Barbagli L, Pacini F.

J Endocrinol Invest. 2018 Jun;41(6):703-709. doi: 10.1007/s40618-017-0794-8. Epub 2017 Dec 11.

PMID:
29230715
16.

Which patient with thyroid cancer deserves systemic therapy and when?

Pacini F.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):291-294. doi: 10.1016/j.beem.2017.08.001. Epub 2017 Aug 18. Review.

PMID:
28911725
17.

Preface.

Pacini F.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):277. doi: 10.1016/j.beem.2017.07.001. No abstract available.

PMID:
28911723
18.

Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients.

Pilli T, Cantara S, Marzocchi C, Cardinale S, Santini C, Cevenini G, Pacini F.

Thyroid. 2017 Aug;27(8):1053-1057. doi: 10.1089/thy.2017.0035. Epub 2017 Jun 12.

PMID:
28605303
19.

Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5.

Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, Capocaccia R, Larrañaga N, Colonna M, Agius D, Ardanaz E, Rubió-Casadevall J, Kowalska A, Virdone S, Mallone S, Amash H, De Angelis R; EUROCARE-5 Working Group.

Eur J Cancer. 2017 May;77:140-152. doi: 10.1016/j.ejca.2017.02.023. Epub 2017 Apr 11.

PMID:
28410490
20.

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.

Brilli L, Danielli R, Ciuoli C, Calabrò L, Di Giacomo AM, Cerase A, Paffetti P, Sestini F, Porcelli B, Maio M, Pacini F.

Endocrine. 2017 Dec;58(3):535-541. doi: 10.1007/s12020-017-1289-2. Epub 2017 Apr 12.

PMID:
28401443
21.

Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis.

Cantara S, Marzocchi C, Pilli T, Cardinale S, Forleo R, Castagna MG, Pacini F.

Int J Mol Sci. 2017 Apr 6;18(4). pii: E775. doi: 10.3390/ijms18040775. Review.

22.

Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome.

Chiofalo F, Ciuoli C, Formichi C, Selmi F, Forleo R, Neri O, Vuolo G, Paffetti P, Pacini F.

Obes Surg. 2017 Jul;27(7):1750-1754. doi: 10.1007/s11695-016-2528-y.

PMID:
28378209
23.

DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients.

Castagna MG, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C, Garbi C, Pacini F, Salvatore D.

J Clin Endocrinol Metab. 2017 May 1;102(5):1623-1630. doi: 10.1210/jc.2016-2587.

PMID:
28324063
24.

Prognostic indicators for papillary thyroid carcinoma.

Maino F, Forleo R, Pacini F.

Expert Rev Endocrinol Metab. 2017 Mar;12(2):101-108. doi: 10.1080/17446651.2017.1309278.

PMID:
30063426
25.

Endopoints for screening thyroid cancer in the Republic of Korea: thyroid specialists' perspectives.

Pacini F.

J Endocrinol Invest. 2017 Jun;40(6):689-690. doi: 10.1007/s40618-017-0613-2. Epub 2017 Feb 16. No abstract available.

PMID:
28205114
26.

American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD.

Thyroid. 2017 Apr;27(4):481-483. doi: 10.1089/thy.2016.0628. Epub 2017 Feb 21. Review.

PMID:
28114862
27.

Papillary thyroid microcarcinoma and active surveillance - Authors' reply.

Leboulleux S, Tuttle RM, Pacini F, Schlumberger M.

Lancet Diabetes Endocrinol. 2016 Dec;4(12):976-977. doi: 10.1016/S2213-8587(16)30326-6. No abstract available.

PMID:
27886753
28.

HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.

Cantara S, Marzocchi C, Castagna MG, Pacini F.

J Endocrinol Invest. 2017 May;40(5):557-560. doi: 10.1007/s40618-016-0583-9. Epub 2016 Nov 21.

PMID:
27873212
29.

Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study.

Essig GF Jr, Porter K, Schneider D, Arpaia D, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas LH, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT.

Thyroid. 2016 Nov;26(11):1563-1572. Epub 2016 Oct 11.

30.

Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?

Leboulleux S, Tuttle RM, Pacini F, Schlumberger M.

Lancet Diabetes Endocrinol. 2016 Nov;4(11):933-942. doi: 10.1016/S2213-8587(16)30180-2. Epub 2016 Aug 20. Review.

PMID:
27550849
31.

Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.

Caria P, Cantara S, Frau DV, Pacini F, Vanni R, Dettori T.

Int J Mol Sci. 2016 Oct 21;17(10). pii: E1759.

32.

Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules.

Rotondi M, Castagna MG, Cappelli C, Ciuoli C, Coperchini F, Chiofalo F, Maino F, Palmitesta P, Chiovato L, Pacini F.

Eur Thyroid J. 2016 Jul;5(2):125-31. doi: 10.1159/000445054. Epub 2016 Apr 27.

33.

Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association.

Biondi B, Bartalena L, Chiovato L, Lenzi A, Mariotti S, Pacini F, Pontecorvi A, Vitti P, Trimarchi F.

J Endocrinol Invest. 2016 Dec;39(12):1465-1474. Epub 2016 Jul 29.

PMID:
27473077
34.

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

Castagna MG, Cantara S, Pacini F.

J Endocrinol Invest. 2016 Oct;39(10):1087-94. doi: 10.1007/s40618-016-0503-z. Epub 2016 Jun 27. Review.

PMID:
27350556
35.

Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer.

Pacini F.

Eur Thyroid J. 2016 Mar;5(1):7-8. doi: 10.1159/000442880. Epub 2016 Jan 16. No abstract available.

36.

Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB).

Rosato L, De Crea C, Bellantone R, Brandi ML, De Toma G, Filetti S, Miccoli P, Pacini F, Pelizzo MR, Pontecorvi A, Avenia N, De Pasquale L, Chiofalo MG, Gurrado A, Innaro N, La Valle G, Lombardi CP, Marini PL, Mondini G, Mullineris B, Pezzullo L, Raffaelli M, Testini M, De Palma M.

J Endocrinol Invest. 2016 Aug;39(8):939-53. doi: 10.1007/s40618-016-0455-3. Epub 2016 Apr 8.

PMID:
27059212
37.

Reply to the Letter to the Editor by Sollini M et al.

Pacini F, Elisei R, Fugazzola L, Ferdeghini M, Mariotti S, Pellegriti G.

J Endocrinol Invest. 2016 Apr;39(4):487-8. doi: 10.1007/s40618-016-0449-1. Epub 2016 Mar 3. No abstract available.

PMID:
26940215
38.

IFNγ-Inducible Chemokines Decrease upon Selenomethionine Supplementation in Women with Euthyroid Autoimmune Thyroiditis: Comparison between Two Doses of Selenomethionine (80 or 160 μg) versus Placebo.

Pilli T, Cantara S, Schomburg L, Cenci V, Cardinale S, Heid EC, Kühn EC, Cevenini G, Sestini F, Fioravanti C, D'Hauw G, Pacini F.

Eur Thyroid J. 2015 Dec;4(4):226-33. doi: 10.1159/000439589. Epub 2015 Oct 8.

39.

Management of advanced medullary thyroid cancer.

Hadoux J, Pacini F, Tuttle RM, Schlumberger M.

Lancet Diabetes Endocrinol. 2016 Jan;4(1):64-71. doi: 10.1016/S2213-8587(15)00337-X. Epub 2015 Oct 23. Review.

PMID:
26608066
40.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L.

Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review.

41.

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI.

Clin Cancer Res. 2016 Jan 1;22(1):44-53. doi: 10.1158/1078-0432.CCR-15-1127. Epub 2015 Aug 26.

42.

Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology.

Pacini F, Brianzoni E, Durante C, Elisei R, Ferdeghini M, Fugazzola L, Mariotti S, Pellegriti G.

J Endocrinol Invest. 2016 Mar;39(3):341-7. doi: 10.1007/s40618-015-0375-7. Epub 2015 Aug 12.

43.

Reference range of serum calcitonin in pediatric population.

Castagna MG, Fugazzola L, Maino F, Covelli D, Memmo S, Sestini F, Fioravanti C, Ferraris Fusarini C, Scapellato C, Macchini F, Cevenini G, Pacini F.

J Clin Endocrinol Metab. 2015 May;100(5):1780-4. doi: 10.1210/jc.2014-4508. Epub 2015 Mar 12.

PMID:
25955324
44.

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.

Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW.

Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24.

45.

Thyroid Cancer.

Pacini F, DeGroot LJ.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2013 Mar 27.

46.

Thyroid Nodules.

Pacini F, De Groot LJ.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2016 Jul 1.

47.

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma.

Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Review.

48.

Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements.

Colato C, Vicentini C, Cantara S, Pedron S, Brazzarola P, Marchetti I, Di Coscio G, Chilosi M, Brunelli M, Pacini F, Ferdeghini M.

Eur J Endocrinol. 2015 May;172(5):571-82. doi: 10.1530/EJE-14-0930. Epub 2015 Feb 19.

PMID:
25698220
49.

Follicular cell-derived thyroid cancer.

Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI.

Nat Rev Dis Primers. 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. Review.

PMID:
27188261
50.

Rare diseases in clinical endocrinology: a taxonomic classification system.

Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Davì MV, degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML.

J Endocrinol Invest. 2015 Feb;38(2):193-259. doi: 10.1007/s40618-014-0202-6. Epub 2014 Nov 7.

PMID:
25376364

Supplemental Content

Loading ...
Support Center